Kymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps a Buy rating on the shares. The company presented the first comprehensive human and translational dataset for KT-621, its oral STAT6 degrader, “showing rapid, deep, and durable” STAT6 knock-down in both blood and skin at low daily doses, the analyst tells investors in a research note. The firm views the data as “convincing.”